Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: Implications for the development of a multicomponent group B vaccine

Journal of Infectious Diseases

Volumn 195, Issue 10, 2007, Pages 1472-1479

  Beernink, Peter T ^a   Welsch, Jo Anne ^a   Harrison, Lee H ^b   Leipus, Arunas ^a   Kaplan, Sheldon L ^c   Granoff, Dan M ^a,d  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5C VACCINE; ANTISERUM; CARRIER PROTEINS AND BINDING PROTEINS; FACTOR H BINDING PROTEIN; FACTOR H BINDING PROTEIN ANTISERUM; MENINGOCOCCUS VACCINE; NADA VACCINE; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; IMMUNOBLOTTING; IMMUNOREACTIVITY; NEISSERIA MENINGITIDIS; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN VARIANT; QUANTITATIVE ANALYSIS; UNITED STATES;

ADHESINS, BACTERIAL; BACTERIAL VACCINES; COMPLEMENT FACTOR H; HUMANS; IMMUNE SERA; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS, SEROGROUP B; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTORS, COMPLEMENT; UNITED STATES; VACCINES, DNA; VARIATION (GENETICS);

EID: 34248166509     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514821     Document Type: Article

References (41)

1. Campbell JD, Edelman R, King JC Jr, Papa T, Ryall R, Rennels MB. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002; 186:1848-51.
2. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159:907-13.
3. Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005; 24:57-62.
4. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 2005; 54:1-21.
5. Cartwright K, Noah N, Peltola H. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. Vaccine 2001; 19:4347-56.
6. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138:4402-7.
7. Devi SJ, Robbins JB, Schneerson R. Antibodies to poly[(2→8)-alpha-N- acetylneuraminic acid] and poly[(2→9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc Natl Acad Sci USA 1991; 88:7175-9.
8. Azmi FH, Lucas AH, Spiegelberg HL, Granoff DM. Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain. Infect Immun 1995; 63:1906-13.
9. Rosenqvist E, Hoiby EA, Wedege E, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995; 63: 4642-52.
10. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281:1520-7.
11. Morley SL, Cole MJ, Ison CA, et al. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr Infect Dis J 2001; 20:1054-61.
12. Tsai CM, Frasch CE, Mocca LF. Five structural classes of major outer membrane proteins in Neisseria meningitidis. J Bacteriol 1981; 146:69-78.
13. Tommassen J, Vermeij P, Struyve M, Benz R, Poolman JT. Isolation of Neisseria meningitidis mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins. Infect Immun 1990; 58:1355-9.
14. van der Ley P, van der Biezen J, Poolman JT. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 1995; 13:401-7.
15. Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 1997; 185:1173-83.
16. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287:1816-20.
17. Grifantini R, Bartolini E, Muzzi A, et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol 2002; 20:914-21.
18. Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002; 195:1445-54.
19. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003; 197:789-99.
20. Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003; 188:1730-40.
21. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006; 103: 10834-9.
22. Rappuoli R. A universal vaccine for serogroup B meningococcus [abstract S10.2]. In: Program and abstracts of the International Pathogenic Neisseria Conference (Cairns, Australia). 2006.
23. Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004; 72:2088-100.
24. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006; 177:501-10.
25. Whaley K, Ruddy S. Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med 1976; 144:1147-63.
26. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med 1977; 146:257-70.
27. Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA 1976; 73:3268-72.
28. Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun 1983; 40:257-64.
29. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001; 8:616-23.
30. Schneider MC, Exley RM, Chan H, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006; 176:7566-75.
31. Ngampasutadol J, Welsch JA, Lewis LA, et al. A novel interaction between factor H SCR 6 and the meningococcal vaccine candidate GNA1870: implications for meningococcal pathogenesis and vaccine development [abstract 6.2.05]. In: Program and abstracts of the International Pathogenic Neisseria Conference (Cairns, Australia). 2006.
32. Harrison LH, Jolley KA, Shutt KA, et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis 2006; 193:1266-74.
33. Kaplan SL, Schutze GE, Leake JA, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 2006; 118: e979-84.
34. Beernink PT, Leipus A, Granoff DM. Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol 2006; 13:758-63.
35. Welsch JA, Rossi R, Comanducci M, Granoff DM. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 2004; 172:5606-15.
36. Mandrell RE, Azmi FH, Granoff DM. Complement-mediated bactericidal activity of human antibodies to poly α2→8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. J Infect Dis 1995; 172:1279-89.
37. Moe GR, Tan S, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 1999; 67:5664-75.
38. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998; 95:3140-5.
39. Capecchi B, Adu-Bobie J, Di Marcello F, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 2005; 55:687-98.
40. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000; 3:445-50.
41. Rappuoli R, Covacci A. Reverse vaccinology and genomics. Science 2003; 302:602.